FDG for dose painting: A rational choice

Radiotherapy and Oncology

Volumn 97, Issue 2, 2010, Pages 163-164

  Aerts, Hugo J W L ^a   Lambin, Philippe ^a   Ruysscher, Dirk De ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EDITORIAL; HUMAN; HYPOXIA; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIOSENSITIVITY;

DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION ROUTES; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 77956161987     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.05.001     Document Type: Editorial

References (35)

1. P. Fournel, G. Robinet, and P. Thomas Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study J Clin Oncol 23 2005 5910 5917
2. K. Furuse, M. Fukuoka, and M. Kawahara Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 1999 2692 2699
3. P. Zatloukal, L. Petruzelka, and M. Zemanova Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study Lung Cancer (Amsterdam, Netherlands) 46 2004 87 98
4. J. Bradley A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group Semin Oncol 32 2005 S111 113
5. J.A. Hayman, M.K. Martel, and R.K. Ten Haken Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial J Clin Oncol 19 2001 127 136
6. S.M. Bentzen Theragnostic imaging for radiation oncology: dose-painting by numbers Lancet Oncol 6 2005 112 117
7. S.M. Bentzen Dose painting and theragnostic imaging: towards the prescription, planning and delivery of biologically targeted dose distributions in external beam radiation oncology Cancer Treat Res 139 2008 41 62
8. D. Thorwarth, S.M. Eschmann, F. Paulsen, and M. Alber Hypoxia dose painting by numbers: a planning study Int J Radiat Oncol Biol Phys 68 2007 291 300
9. Y. Kim, Q. Lin, P.M. Glazer, and Z. Yun Hypoxic tumor microenvironment and cancer cell differentiation Curr Mol Med 9 2009 425 434
10. L. Dubois, W. Landuyt, and L. Cloetens [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model Eur J Nucl Med Mol Imaging 36 2009 209 218
11. D. Thorwarth, S.M. Eschmann, J. Scheiderbauer, F. Paulsen, and M. Alber Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer BMC Cancer 5 2005 152
12. K.A. Krohn, J.M. Link, and R.P. Mason Molecular imaging of hypoxia J Nucl Med 49 2008 129S 148S
13. L. Bentzen, S. Keiding, M.R. Horsman, T. Gronroos, S.B. Hansen, and J. Overgaard Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing Acta Oncol 41 2002 304 312
14. M.E. Phelps Inaugural article: positron emission tomography provides molecular imaging of biological processes Proc Natl Acad Sci USA 97 2000 9226 9233
15. H. Jadvar, A. Alavi, and S.S. Gambhir 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization J Nucl Med 50 2009 1820 1827
16. J.F. Vansteenkiste, S.G. Stroobants, and P.J. Dupont Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose- positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group J Clin Oncol 17 1999 3201 3206
17. S.M. Eschmann, G. Friedel, and F. Paulsen Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 33 2006 263 269
18. G.R. Borst, J.S. Belderbos, and R. Boellaard Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer Eur J Cancer 41 2005 1533 1541
19. R.J. Downey, T. Akhurst, and M. Gonen Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection J Clin Oncol 22 2004 3255 3260
20. A. van Baardwijk, C. Dooms, and R.J. van Suylen The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer Eur J Cancer 43 2007 1392 1398
21. R. Boellaard Standards for PET image acquisition and quantitative data analysis J Nucl Med 50 2009 11S 20S
22. R. Boellaard, W.J. Oyen, and C.J. Hoekstra The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials Eur J Nucl Med Mol Imaging 35 2008 2320 2333
23. J.W. Kim, and C.V. Dang Cancer's molecular sweet tooth and the Warburg effect Cancer Res 66 2006 8927 8930
24. O. Feron Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells Radiother Oncol 92 2009 329 333
25. H. Vesselle, R.A. Schmidt, and J.M. Pugsley Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography Clin Cancer Res 6 2000 3837 3844
26. C. Dooms, A. van Baardwijk, and E. Verbeken Association between 18F-fluoro-2-deoxy-d-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer J Thorac Oncol 4 2009 822 828
27. R. Airley, J. Loncaster, and S. Davidson Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix Clin Cancer Res 7 2001 928 934
28. U.G. Sattler, and W. Mueller-Klieser The anti-oxidant capacity of tumour glycolysis Int J Radiat Biol 85 2009 963 971
29. M. Shanmugam, S.K. McBrayer, and S.T. Rosen Targeting the Warburg effect in hematological malignancies: from PET to therapy Curr Opin Oncol 21 2009 531 536
30. J.A. Menendez, and R. Lupu Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis Nat Rev Cancer 7 2007 763 777
31. C. Schutze, R. Bergmann, and A. Yaromina Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice Radiother Oncol 83 2007 311 315
32. H.J. Aerts, A.A. van Baardwijk, and S.F. Petit Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan Radiother Oncol 91 2009 386 392
33. A. Abramyuk, S. Tokalov, and K. Zophel Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer? Radiother Oncol 91 2009 399 404
34. H.J. Aerts, G. Bosmans, and A.A. van Baardwijk Stability of 18F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study Int J Radiat Oncol Biol Phys 71 2008 1402 1407
35. I. Madani, W. Duthoy, and C. Derie Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer Int J Radiat Oncol Biol Phys 68 2007 126 135